Clinical trial
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors…
NCT02628067 · Merck Sharp & Dohme LLC, Industry · Active, not recruiting
Key facts
| NCT number | NCT02628067 |
|---|---|
| Title | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) |
| Official title | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer and 15 more |
| Intervention type | Biological |
| Interventions | pembrolizumab |
| Enrollment | 1,609 |
| Start date | Dec 18, 2015 |
| Primary completion | May 4, 2027 |
| Completion | May 4, 2027 |
| First posted | Dec 11, 2015 |
| Last update posted | Sep 22, 2025 |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: